Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VM-1500 with Raltegravir or Darunavir in Healthy Volunteers
NCT02489487Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elsufavirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Viriom Inc. Primary endpoint: Number of participants with treatment-related adverse events at 36 days. Started Sep 2014; status: completed.
02
Drugs
elsufavirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02489487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489487.